Aspect Biosystems is at the forefront of regenerative medicine, leveraging its proprietary microfluidic 3D bioprinting technology to create living, patient-specific cell therapies. The company focuses on developing treatments for currently incurable diseases by precisely engineering functional human tissues. Their platform technology enables the creation of advanced therapeutics that aim to replace, repair, or regenerate damaged tissues and organs.
Serves as the primary center for research and development, bioprocess development, corporate operations, and strategic partnerships. It houses their advanced bioprinting labs and scientific teams.
State-of-the-art bioprinting laboratories, advanced cell culture facilities, and collaborative research spaces designed to foster innovation in tissue engineering.
A dynamic and innovative environment driven by a multidisciplinary team of scientists, engineers, and business professionals. The culture emphasizes collaboration, scientific rigor, and a shared passion for developing transformative therapies.
The Vancouver headquarters is crucial as it's the birthplace of Aspect's core technology and the central hub for their pioneering work in developing bioprinted therapeutics for global health challenges.
While headquartered in Vancouver, Canada, Aspect Biosystems engages in global collaborations with pharmaceutical companies, academic institutions, and research organizations to advance its bioprinted therapies. Their partnerships (e.g., with Novo Nordisk, J&J Innovation, JDRF) and research efforts have an international scope, aiming to address global health needs. They also present their research at international conferences and engage with a global scientific community.
170 - 887 Great Northern Way
Vancouver
BC
Canada
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aspect Biosystems' leadership includes:
Aspect Biosystems has been backed by several prominent investors over the years, including:
No major C-suite executive hires or departures have been publicly announced by Aspect Biosystems in the last 12 months (May 2023 - May 2024). The existing leadership team appears stable as they advance their bioprinting platform and therapeutic programs.
Discover the tools Aspect Biosystems uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aspect Biosystems commonly utilizes the email format combining the first initial of an employee's first name followed by their full last name. Other formats may exist but this is the most frequently observed pattern.
[first_initial][last_name]@aspectbiosystems.com
Format
tmohamed@aspectbiosystems.com
Example
75%
Success rate
Aspect Biosystems Press Release • December 5, 2023
Aspect Biosystems announced the successful close of an oversubscribed CAD $49 million (approximately USD $36 million) Series B financing round. The funding was led by Rhadius Capital and included participation from new and existing investors such as Pangaea Ventures and Novo Holdings. These funds will be used to advance Aspect's pipeline of bioprinted cell therapies, scale its manufacturing capabilities, and expand its technology platform....more
Aspect Biosystems Press Release • March 4, 2024
Aspect Biosystems announced it would present new preclinical data on its lead program, a bioprinted liver tissue therapeutic (AB-LVT01) for Alpha-1 Antitrypsin Deficiency (AATD), at the European Association for the Study of the Liver (EASL) Congress 2024. The presentation highlights the potential of their platform to address liver diseases....more
Aspect Biosystems Press Release • May 23, 2023
Aspect Biosystems and JDRF Canada announced a research collaboration aimed at developing a novel bio-printed therapeutic for type 1 diabetes. The partnership will leverage Aspect's bioprinting technology to create implantable, insulin-producing tissues, with funding support from JDRF Canada....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aspect Biosystems, are just a search away.